amifampridine has been researched along with Neuromuscular Diseases in 2 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Neuromuscular Diseases: A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palace, J | 1 |
| Wiles, CM | 1 |
| Newsom-Davis, J | 1 |
| Bournaud, R | 1 |
| Mallart, A | 1 |
1 trial available for amifampridine and Neuromuscular Diseases
| Article | Year |
|---|---|
3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Electromyography; Female; Humans; Male; Mi | 1991 |
1 other study available for amifampridine and Neuromuscular Diseases
| Article | Year |
|---|---|
Potassium channel blockers and impulse propagation in murine motor endplate disease.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; In Vitro Techniques; Ion | 1987 |